Geftinat Gefitinib 250 Mg

Get a Price/Quote

MOQ : 100 Boxes

Geftinat Gefitinib 250 Mg Specification

Indication
Non-small cell lung cancer (NSCLC)

Dosage Form
Tablets

Salt Composition
Gefitinib 250 mg

Feature
Targeted therapy, oral administration

Application
Anticancer therapy

Physical Color/Texture
White to off-white film-coated tablets

Storage Instructions
Store at room temperature, away from direct light and moisture

Shelf Life
24 months

Storage Condition
Keep container tightly closed

Therapeutic Class
Antineoplastic Agents (EGFR Inhibitor)

Prescription/Non prescription
Prescription Only Medicine

Strength
250 mg per tablet

Administration Route
Oral

Brand Name
Geftinat

International Availability
Exported to Canada, Europe, UK, USA, Australia

Packaging Size
30 Tablets per Bottle

Geftinat Gefitinib 250 Mg Trade Information

Minimum Order Quantity
100 Boxes

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Boxes Per Month

Delivery Time
2-10 Days

Main Domestic Market
All India

Geftinat Gefitinib 250 Mg About

Geftinat Gefitinib 250 Mg stands as a distinguished oral anticancer therapy, pivotal in the targeted treatment of non-small cell lung cancer (NSCLC). Manufactured in India by a renowned supplier, this latest antineoplastic agent features a packaging size of 30 tablets per bottle, with each tablet containing 250 mg of Gefitinib. Geftinat is exclusively available by prescription and is internationally exported to Canada, Europe, UK, USA, and Australia. This EGFR inhibitor's advanced formulation and robust export offer make it an indispensable choice for both patients and healthcare professionals seeking reliable, effective, and high-quality NSCLC treatment solutions. Store in a tightly closed container at room temperature, away from moisture and light, for optimal shelf life.

Versatile Applications and Suitability of Geftinat Gefitinib 250 Mg

Geftinat Gefitinib 250 Mg presents a specialized application surface in the management of non-small cell lung cancer (NSCLC). Its use as an oral targeted therapy enhances patient convenience and compliance. Beyond its pivotal NSCLC indication, Geftinat's targeted mechanism makes it suitable for approved EGFR-mutated cases and potentially valuable for research in similar oncological conditions. The film-coated, white-to-off-white tablets ensure ease of administration, making it highly suitable for use in clinical settings specializing in anticancer therapies.

Domestic Availability, Packaging, and Delivery Terms for Geftinat Gefitinib

The main domestic market for Geftinat Gefitinib 250 Mg is India, with robust supply ability to meet ongoing demand. The packaging ensures product integrity and patient safety, delivered in tightly sealed bottles of 30 tablets each. Competitive offers and secure payment terms enhance customer accessibility, making procurement efficient for authorized buyers. Delivery options are reliable, and prompt shipment is made possible due to efficient trading channels, reinforcing the brand's reputation for high-quality and trustworthy pharmaceutical solutions.

FAQ's of Geftinat Gefitinib 250 Mg:

Q: How should Geftinat Gefitinib 250 Mg tablets be stored for best efficacy?

A: Store Geftinat Gefitinib 250 Mg tablets in a tightly closed container at room temperature, away from direct light and moisture, to maintain the medication's efficacy throughout its 24-month shelf life.

Q: What is the primary indication for Geftinat Gefitinib 250 Mg tablets?

A: Geftinat Gefitinib 250 Mg is mainly indicated for the treatment of non-small cell lung cancer (NSCLC) and is prescribed as a targeted oral therapy, particularly in cases involving EGFR mutations.

Q: Where is Geftinat Gefitinib 250 Mg made available for export?

A: Geftinat Gefitinib is exported to several international markets, including Canada, Europe, the UK, the USA, and Australia, ensuring worldwide accessibility for eligible patients via authorized distribution channels.

Q: What benefits does Geftinat Gefitinib offer compared to traditional chemotherapy?

A: Geftinat delivers targeted epithelial growth factor receptor (EGFR) inhibition, which may result in a more favorable safety profile and improved tolerability compared to conventional chemotherapy, offering a modern approach to NSCLC therapy.

Q: How is Geftinat Gefitinib 250 Mg administered and what is its dosage form?

A: Geftinat is administered orally as a tablet, with each bottle containing 30 white to off-white film-coated tablets, making it easy for eligible patients to incorporate into their daily treatment regimen.

Tell us about your requirement